$ADMA News
Last published 1w ago
- 1w agoADMAADMA BIOLOGICS, INC. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoADMAADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year
- 2w agoADMAADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S.-based, end-to-end commercial biopharmaceutical company
- 3w agoADMAADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing ProcessGlobeNewswireOptimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield No Thromboembolic Events Were Reported for ADMA IVIG Products Manufactured
- 3mo agoADMAADMA Q2 2026 Financial Results - ADMA BIOLOGICS INCEarnings Call TranscriptsGood afternoon and welcome to the AdmoBiologics second quarter 2026 financial results and business update conference call on Wednesday, August 5th, 2026. At this time, all participants are in a listen-only mode. There wi
- 3mo agoADMAADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and
- 3mo agoADMAADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.GlobeNewswireNEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ:ADMA) ("ADMA Biologics" or the "Company") for potential
- 3mo agoADMAThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA Biologics, Inc. Lawsuit - ADMAGlobeNewswireNEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ:ADMA). Shareholders who purchased shares of ADMA during the class period
- 3mo agoADMASueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMAPR NewswireSueWallSt notifies investors that Jerrold V. Grossman, founder and Vice Chairman of ADMA Biologics, Inc. (NASDAQ: ADMA), is named as a defendant in a ...
- 3mo agoADMAADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswireConference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S.
- 3mo agoADMAPODDINTUPSIXImportant Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); Insulet Corporation (NASDAQ: PODD); Intuit Inc. (INTU); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE) -- ADMA BIOLOGICS, INC. (NASDAQ:ADMA): Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ:ADMA) breached their
- 4mo agoADMACVLTERASHUBGImportant Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); Commvault Systems, Inc. (NASDAQ: CVLT); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, July 14, 2026 (GLOBE NEWSWIRE) -- ADMA BIOLOGICS, INC. (NASDAQ:ADMA): Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ:ADMA) breached their
- 4mo agoADMASueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMAGlobeNewswireJerrold V. Grossman, ADMA Biologics co-founder and Vice Chairman, signed annual reports that allegedly concealed channel stuffing and an undisclosed related party distributor operating from ADMA's own headquarters.
- 4mo agoADMAREMINDER: ADMA Biologics, Inc. Investors With Significant Losses Must Act By August 10, 2026 – Kirby McInerney LLPGlobeNewswireNEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA) investors of the August 10, 2026 deadline to seek the role of lead
- 4mo agoADMAWGSNAVNNUAIImportant Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (FKA New Era Helium (NASDAQ: NEHC)): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, July 07, 2026 (GLOBE NEWSWIRE) -- ADMA BIOLOGICS, INC. (NASDAQ:ADMA): Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ:ADMA) breached their
- 4mo agoADMAADMA INVESTOR REMINDER: ADMA Biologics, Inc. Investors Have Until August 10, 2026 To Seek Lead Plaintiff RoleBusiness WireIf you have suffered a loss on your ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill
- 4mo agoADMAADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.GlobeNewswireNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ:ADMA) ("ADMA Biologics" or the "Company") for potential
- 5mo agoADMAADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover LossesGlobeNewswireBOSTON, June 10, 2026 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of its executives. Investors who have lost
- 5mo agoADMALowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the FirmGlobeNewswireNEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ:ADMA) ("ADMA Biologics" or the
- 6mo agoADMALowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the FirmGlobeNewswireNEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ:ADMA) ("ADMA Biologics" or the
- 6mo agoADMABREAKING: ADMA Biologics Shares Fall Over 24%; Investors Encouraged to Contact Block & Leviton to Possibly Recover LossesGlobeNewswireBOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ:ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc.
- 6mo agoADMAADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income(1) of $40.7 Million, 22% Year-Over-Year Growth
- 6mo agoADMAADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and OlderGlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to
- 6mo agoADMAADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026GlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to
- 7mo agoADMAADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.GlobeNewswireNEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ:ADMA) ("ADMA Biologics" or the "Company") for potential violations of the
- 7mo agoADMALowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the FirmGlobeNewswireNEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ:ADMA) ("ADMA Biologics" or the
- 7mo agoADMAADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock DropPR NewswireLeading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of ...
- 7mo agoADMAADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudBusiness WireThe law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior
- 7mo agoADMAADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper ResearchGlobeNewswireShort seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not
- 7mo agoADMAADMA Biologics Addresses Misleading Short-Seller ReportGlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to
- 8mo agoADMAADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase InitiativeGlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to
- 8mo agoADMAADMA Q4 2025 Financial Results - ADMA BIOLOGICS INCEarnings Call TranscriptsGood afternoon and welcome to the ADMA Biologics Full Year 2025 Financial Results and Business Update Conference Call on Wednesday, February 25, 2026. At this time, all participants are in a listen-only mode. There will
- 8mo agoADMAADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireFY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million,
- 8mo agoADMAADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026GlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to
- 10mo agoADMAADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business UpdateGlobeNewswireFY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reiterated Year-End 2025
- 10mo agoADMAADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026GlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to
- 1y agoADMAADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA(1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income(2)
- 1y agoADMAADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025GlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to
- 1y agoADMAADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoADMAADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA(1) of
- 1y agoADMAADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025GlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to
- 1y agoADMAADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an
- 1y agoADMAADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025GlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to
- 1y agoADMAAVAIPOAIRXRX+1Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant GrowthGlobeNewswirePALM BEACH, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to reports from industry insiders the Global AI in Diabetic Retinopathy market is projected to continue to grow at a
- 1y agoADMAADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement ProcessGlobeNewswireApproval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's
- 1y agoADMAADMA Biologics Statement on TariffsGlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,
- 1y agoADMABREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of ControlsGlobeNewswireBOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ:ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc.
- 1y agoADMAADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireFY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1) of $164.6
- 1y agoADMAADMA Biologics to Participate in the Raymond James Institutional Investor ConferenceGlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,
- 1y agoADMAADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025GlobeNewswireRAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,